发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr.
发布时间
101 天前
2026-06-29 19:59:18 UTC
源站更新
101 天前
2026-06-29 21:11:41 UTC
首次抓取
101 天前
2026-06-29 20:04:37 UTC
FDA 新组建的肽类药物咨询委员会成员多为肽类产品推广者，与行业有财务关联，引发对其决策客观性的担忧。
The FDA's new advisory panel to review peptide drugs is largely composed of doctors and pharmacists with financial ties to the peptide industry, raising concerns about conflicts of interest, as the substances are promoted by RFK Jr. and others but face safety questions.
用于追踪这条内容的来源与记录标识。
